Platinum eye drops and light to slow keratoconus
Part of Eyes & vision clinical trials.
This Phase 1 study tests whether a specific corneal cross-linking system (called PXL-Platinum 330) is safe and effective for people with progressive keratoconus, a condition that makes the cornea thin and bulge. The goal is to slow vision changes and see how well the treatment works in the short term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 12 years old
- Have keratoconus that is getting worse over the last 3+ months (based on exam and tests)
- Have corneal shape and measurements that match keratoconus, such as steepening in the center/bottom of the cornea and specific topography scan results
- Have a cornea thickness above a safety cutoff (thinnest point must be 485 microns or more)
- Be willing and able to come back for follow-up visits
- Not be pregnant or breastfeeding during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different UV light exposure times (18 minutes vs. 24 minutes) during a corneal crosslinking procedure for people with keratoconus or similar corneal thinning conditions. The goal is to see if the shorter time works as well as the longer one.
This trial tests a treatment called corneal cross-linking (CXL) using vitamin B2 (riboflavin) drops and UV light to strengthen the cornea and slow down thinning. It is for people with keratoconus, post-surgical thinning, or certain corneal infections that are getting worse.
This trial studies collagen cross-linking, a procedure meant to strengthen a weakened cornea in people with keratoconus. It may help slow the bulging/weakening of the cornea and improve vision, and the study also uses special imaging to check changes over time.
This Phase 2 study tests how safe and well a corneal cross-linking device (called PXL-Platinum 330) works for people with corneal ectasia (a thinning/steepening of the cornea). If you qualify, the goal is to help stop or slow further worsening of your cornea shape and improve eye stability.
This Phase 2 study tests whether a procedure called PXL‑Platinum 330 can safely and effectively strengthen corneas that are thinning (such as keratoconus or related conditions). It aims to see if the treatment can help stabilize or improve the cornea’s shape while keeping side effects low.
This study tests a procedure called corneal crosslinking to slow or stop the progression of keratoconus or corneal ectasia. It might help keep your cornea stable and prevent further vision loss.
Hear when a new Keratoconus, Unstable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.